The Cocktail Report (sound really smart around your friends):
Researchers at Seragon Biosciences published a peer-reviewed study showing that SRN-901, a five-compound oral drug, extended median remaining lifespan by 33% in 18-month-old mice compared to placebo, with a 46% reduction in the hazard of death.
SRN-901 contains five ingredients: urolithin A (a gut-derived compound that promotes mitophagy, the cellular recycling of damaged mitochondria), quercetin (a plant flavonoid with anti-inflammatory and senolytic properties), nicotinamide riboside (an NAD+ precursor that fuels cellular energy and repair), alpha-lipoic acid (an antioxidant that activates AMPK, a key metabolic regulator), and SRN-820, a proprietary mTOR pathway modulator.
SRN-901 outperformed rapamycin, NMN, and NR individually. Rapamycin extended lifespan modestly; NMN and NR showed no statistically significant lifespan benefit in this study.
Mice on SRN-901 showed 70% attenuation of frailty progression, remained well-groomed with normal posture at 64 weeks, and had 30% lower tumor incidence compared to placebo.
Blood analysis revealed SRN-901 reversed 78 age-related metabolite changes, upregulated DNA repair and glutathione pathways, and suppressed inflammation, mTOR, and Alzheimer's disease-associated gene pathways.
If you have been tracking the longevity space, you have probably noticed a pattern: single compounds like NAD+ precursors or rapamycin show promise in isolation but rarely produce dramatic results. SRN-901 was designed to test a different hypothesis: that targeting multiple aging pathways simultaneously might unlock benefits no single ingredient can achieve on its own.
The study enrolled 160 C57BL/6 mice at 18 months of age, which roughly corresponds to late-middle to early-old age in humans. This matters for you personally: most longevity studies start treatment in young animals, making it hard to know whether results apply to someone who already has decades of living behind them.
Mice receiving SRN-901 survived a median of 350.5 additional days, compared to 263.5 days for placebo. That 33% gain came alongside meaningful quality-of-life improvements, including frailty scores that rose only 17% above baseline in treated mice, versus 57% in placebo mice.
At the 64-week mark, placebo mice appeared visibly aged and unkempt, while SRN-901 mice maintained normal grooming and posture. Tumor incidence was also 30% lower in treated animals.
The molecular data helps explain why. Transcriptomic analysis (a gene-wide analysis of which genes are switched on or off) found SRN-901 downregulated inflammation, mTOR signaling, and reactive oxygen species pathways while upregulating DNA repair.
Metabolomic profiling of whole blood found 78 age-related metabolic changes that were partially reversed by treatment. Glutathione metabolism, insulin signaling, and AMPK signaling all trended younger in treated mice.
To be candid, this study was conducted by Seragon Biosciences, the company that makes SRN-901, and the work was done entirely in mice. No human trial of this specific combination has been conducted yet.
For readers already experimenting with longevity supplements, SRN-901's core ingredients are not exotic. What this study argues is that the combination, and the specific ratios, may matter more than any single compound taken alone.
Why Should You Care?
This study offers compelling mouse-model evidence that combining multiple aging pathways simultaneously produces results no single compound can match. If you are already thinking about which supplements to take or whether rapamycin is worth exploring, SRN-901 reframes the question: it may not be about finding the one right compound; it may be about targeting aging from several directions at once.
Sources:
Weiss B, Miranda DR, Arrazati D, et al. SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways. Drug Des Devel Ther. 2026 Apr 15;20:594895. doi: 10.2147/DDDT.S594895. PMC13092247. https://pmc.ncbi.nlm.nih.gov/articles/PMC13092247/
